Kiniksa Pharmaceuticals Analyst Ratings
Kiniksa Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/26/2023 | 64.27% | Goldman Sachs | $22 → $32 | Maintains | Buy |
| 03/09/2023 | 2.67% | JP Morgan | $19 → $20 | Maintains | Overweight |
| 12/29/2021 | 74.54% | B of A Securities | $37 → $34 | Maintains | Buy |
| 04/01/2020 | 28.34% | B of A Securities | → $25 | Initiates Coverage On | → Buy |
| 03/11/2020 | 23.2% | JP Morgan | $22 → $24 | Maintains | Overweight |
| 12/06/2019 | -7.6% | Goldman Sachs | $16 → $18 | Upgrades | Neutral → Buy |
| 08/14/2019 | 79.67% | JMP Securities | $44 → $35 | Maintains | Market Outperform |
| 03/11/2019 | 33.47% | Barclays | → $26 | Initiates Coverage On | → Overweight |
| 12/12/2018 | 69.4% | Wedbush | $31 → $33 | Reiterates | Outperform → Outperform |
| 09/17/2018 | 125.87% | JMP Securities | $33 → $44 | Maintains | Market Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 07/26/2023 | 64.27% | 高盛 | 22 美元 → 32 美元 | 维护 | 购买 |
| 03/09/2023 | 2.67% | 摩根大通 | 19 美元 → 20 美元 | 维护 | 超重 |
| 12/29/2021 | 74.54% | B of A 证券 | 37 美元 → 34 美元 | 维护 | 购买 |
| 2020 年 1 月 4 日 | 28.34% | B of A 证券 | → 25 美元 | 启动覆盖开启 | → 购买 |
| 03/11/2020 | 23.2% | 摩根大通 | 22 美元 → 24 美元 | 维护 | 超重 |
| 2019 年 6 月 12 日 | -7.6% | 高盛 | 16 美元 → 18 美元 | 升级 | 中性 → 买入 |
| 08/14/2019 | 79.67% | JMP 证券 | 44 美元 → 35 美元 | 维护 | 市场跑赢大盘 |
| 2019 年 11 月 3 日 | 33.47% | 巴克莱 | → 26 美元 | 启动覆盖开启 | → 超重 |
| 2018 年 12 月 12 日 | 69.4% | Wedbush | 31 美元 → 33 美元 | 重申 | 跑赢大盘 → 跑赢大盘 |
| 09/17/2018 | 125.87% | JMP 证券 | 33 美元 → 44 美元 | 维护 | 市场跑赢大盘 |
What is the target price for Kiniksa Pharmaceuticals (KNSA)?
Kiniksa Pharmicals（KNSA）的目标价格是多少？
The latest price target for Kiniksa Pharmaceuticals (NASDAQ: KNSA) was reported by Goldman Sachs on July 26, 2023. The analyst firm set a price target for $32.00 expecting KNSA to rise to within 12 months (a possible 64.27% upside). 2 analyst firms have reported ratings in the last year.
高盛于2023年7月26日公布了Kiniksa Pharmicals（纳斯达克股票代码：KNSA）的最新目标股价。这家分析公司将目标股价定为32.00美元，预计KNSA将在12个月内升至12个月内（可能上涨64.27％）。去年有2家分析公司公布了评级。
What is the most recent analyst rating for Kiniksa Pharmaceuticals (KNSA)?
Kiniksa Pharmicals（KNSA）的最新分析师评级是多少？
The latest analyst rating for Kiniksa Pharmaceuticals (NASDAQ: KNSA) was provided by Goldman Sachs, and Kiniksa Pharmaceuticals maintained their buy rating.
Kiniksa Pharmicals（纳斯达克股票代码：KNSA）的最新分析师评级由高盛提供，Kiniksa Pharmicals维持买入评级。
When is the next analyst rating going to be posted or updated for Kiniksa Pharmaceuticals (KNSA)?
Kiniksa Pharmicals（KNSA）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kiniksa Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kiniksa Pharmaceuticals was filed on July 26, 2023 so you should expect the next rating to be made available sometime around July 26, 2024.
分析师在进行了广泛的研究（包括浏览公开财务报表、与Kiniksa Pharmicals的高管和客户交谈以及听取财报电话会议）后得出股票评级。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。Kiniksa Pharmicals的最新评级是在2023年7月26日提交的，因此您应该预计下一个评级将在2024年7月26日左右公布。
Is the Analyst Rating Kiniksa Pharmaceuticals (KNSA) correct?
分析师对Kiniksa Pharmicals（KNSA）的评级正确吗？
While ratings are subjective and will change, the latest Kiniksa Pharmaceuticals (KNSA) rating was a maintained with a price target of $22.00 to $32.00. The current price Kiniksa Pharmaceuticals (KNSA) is trading at is $19.48, which is out of the analyst's predicted range.
尽管评级是主观的，将会发生变化，但最新的Kiniksa Pharmicals（KNSA）评级维持不变，目标股价为22.00美元至32.00美元。Kiniksa Pharmicals（KNSA）目前的交易价格为19.48美元，超出了分析师的预测区间。